Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Infectious Diseases, antiviral therapy, broad-spectrum antiviral agents, host-targeting antivirals, immune modulation, nucleoside analogues, CHRONIC HEPATITIS-C, VIRUS-REPLICATION, IN-VITRO, DOUBLE-BLIND, POLYMERASE INHIBITOR, 3C-LIKE PROTEASES, VIRAL REPLICATION, ENVELOPED VIRUSES, INTERFERON-ALPHA, ORAL RIBAVIRIN, Antiviral Agents, Communicable Diseases, Emerging, DNA-Directed RNA Polymerases, Drug Discovery, Humans, Nucleosides, RNA Viruses, Viral Proteins, Virus Diseases, Virus Internalization, Virus Replication, 0605 Microbiology, 1103 Clinical Sciences, 1108 Medical Microbiology, Microbiology, 3202 Clinical sciences

Abstract:

Potent antivirals are successfully used for the treatment of infections with herpesviruses, hepatitis B and C viruses, HIV, and with some success for influenza viruses. However, no selective inhibitors are available for a multitude of medically important viruses, most of which are (re-)emerging RNA viruses. As it is impossible to develop drugs against each of these viruses, broad-spectrum antiviral agents (BSAA) are a prime strategy to cope with this challenge.